VRNA_OUT_1 [2025-04-30 12:35:59 -0400] 1994 Bytes | 452 tokens | Cum: 452 tkns (5.65% of 8k)
==========================================================================

By the grace of fortune and the swing of fate, Verona Pharma (VRNA) hath moved from $73.22 to $72.10. 'Tis 12:35 PM on Wed Apr 30, 2025. We must needs inquire—doth this path lead unto riches or ruin?

--- COMPANY PROFILE ---
Company: Verona Pharma (VRNA)
IPO: 2017-04-27 (8 Years Ago)
Market Cap: $4,634,336,686
Shares Outstanding: 632,890,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Verona Pharma (VRNA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: - To load a new set of information and menu options, reply with: `NEX`

VRNA_OUT_3 [2025-04-30 12:36:00 -0400] 2073 Bytes | 624 tokens | Cum: 1078 tkns (13.48% of 8k)
==========================================================================

Today 03:12AM - Verona Pharma PLC (VRNA) Q1 2025 Earnings Call Highlights: Strong Ohtuvayre Sales Propel ...
Apr-29-25 03:45PM - Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
Apr-29-25 03:45PM 06:00AM - Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr-28-25 07:26PM - Verona Pharma PLC (VRNA) Q1 2025: Everything You Need To Know Ahead Of Earnings
Apr-23-25 05:48PM - Verona Pharma plc (VRNA): Among the Best Multibagger Stocks to Buy According to Billionaires
Apr-23-25 05:48PM 02:58PM - TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary
Apr-19-25 05:30AM - ClearBridge Small Cap Strategy Q1 2025 Commentary
Apr-17-25 04:53AM - Ritedose to double single-vial packaging capabilities with seventh Syntegon line
Apr-15-25 06:00AM - Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
Apr-07-25 10:47AM - Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Mar-30-25 03:00AM - Putnam Small Cap Growth Fund Q4 2024 Commentary

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-29T10:00:00Z - Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
B2 - 2025-04-15T10:00:00Z - Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
B3 - 2025-02-13T11:00:00Z - Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
B4 - 2025-01-21T18:00:00Z - Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight
B5 - 2025-01-07T11:00:00Z - Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
B6 - 2024-11-04T07:00:00Z - Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VRNA_OUT_5 [2025-04-30 12:36:01 -0400] 880 Bytes | 240 tokens | Cum: 1320 tkns (16.50% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/29/3069977/0/en/Verona-Pharma-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.htmlVerona Pharma reported strong Q1 2025 results, with Ohtuvayre net sales of $71.3 million and over 25,000 prescriptions filled. The company plans to expand its sales team and advance its clinical pipeline, including a Phase 2b study for a fixed-dose combination of ensifentrine and glycopyrrolate.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_7 [2025-04-30 12:36:02 -0400] 505 Bytes | 140 tokens | Cum: 1462 tkns (18.27% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S10 - 2025-04-29 10-Q PART I - FIN INFO

Item 1. Fin statements

Verona Pharma plc

Condensed Cons Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

March 31, December 31, 2025 2024 ASSETS Curr assets: Cash and cash equiv $ 401...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VRNA_OUT_9 [2025-04-30 12:36:03 -0400] 1182 Bytes | 363 tokens | Cum: 1827 tkns (22.84% of 8k)
==========================================================================

Showing S10 (chunk 1 of 6): S10:
PART I - FINANCIAL INFORMATION

Item 1. Financial statements

Verona Pharma plc

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

March 31, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 401,415 $ 399,757 Accounts receivable, net 62,159 31,496 Prepaid expenses 11,317 7,573 Tax incentive receivable 5,935 5,762 Inventory 7,244 6,249 Other current assets 12,955 2,735 Total current assets 501,025 453,572 Non-current assets: Furniture and equipment, net 1,048 1,105 Inventory, long-term 6,508 1,972 Goodwill 545 545 Equity interest 15,000 15,000 Right-of-use assets 1,810 2,048 Total non-current assets 24,911 20,670 Total assets $ 525,936 $ 474,242 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Accounts payable $ 9,077 $ 11,266 Accrued expenses 32,335 16,757 Royalties payable 4,487 1,100 Revenu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_11 [2025-04-30 12:36:04 -0400] 1182 Bytes | 338 tokens | Cum: 2167 tkns (27.09% of 8k)
==========================================================================

Showing S10 (chunk 2 of 6): e interest purchase security agreement 687 Current operating lease liabilities 1,078 1,120 Taxes payable 8,889 8,889 Other current liabilities 678 2,862 Total current liabilities 56,544 42,681 Non-current liabilities: Term loan 241,742 120,341 Revenue interest purchase security agreement 105,420 Non-current operating lease liabilities 1,055 1,241 Total non-current liabilities 242,797 227,002 Total liabilities 299,341 269,683 Commitments and contingencies Shareholders' equity: Ordinary 0.05 par value shares; 703,189,462 and 703,189,462 issued, and 681,056,022 and 677,008,254 outstanding, at March 31, 2025 and December 31, 2024, respectively

45,021 45,021 Additional paid-in capital 766,369 728,199 Ordinary shares held in treasury ( 1,402 ) ( 1,659 ) Accumulated other comprehensive loss ( 4,601 ) ( 4,601 ) Accumulated deficit ( 578,792 ) ( 562,401 ) Total shareholders' equity 226,595 204,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_13 [2025-04-30 12:36:05 -0400] 1182 Bytes | 315 tokens | Cum: 2484 tkns (31.05% of 8k)
==========================================================================

Showing S10 (chunk 3 of 6): 559 Total liabilities and shareholders' equity $ 525,936 $ 474,242

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Verona Pharma plc

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except per share amounts)

Three months ended March 31, 2025 2024 Revenue: Product sales, net $ 71,256 $ Other revenue 5,000 Total revenue, net 76,256 Operating expenses: Cost of sales 3,407 Research and development 14,054 6,764 Selling, general and administrative 69,112 20,434 Total operating expenses 86,573 27,198 Operating loss ( 10,317 ) ( 27,198 ) Other income/(expense): Research and development tax credit 585 Loss on extinguishment of debt ( 407 ) Interest income 3,891 3,378 Interest expense ( 10,195 ) ( 1,586 ) Foreign exchange gain/(loss) 470 ( 219 ) Total other (expense)/income, net

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_15 [2025-04-30 12:36:05 -0400] 1182 Bytes | 332 tokens | Cum: 2818 tkns (35.23% of 8k)
==========================================================================

Showing S10 (chunk 4 of 6): ( 6,241 ) 2,158 Loss before income taxes ( 16,558 ) ( 25,040 ) Income tax benefit/(expense) 239 ( 754 ) Net loss $ ( 16,319 ) $ ( 25,794 ) Loss per ordinary share - basic and diluted $ ( 0.02 ) $ ( 0.04 ) Weighted-average shares outstanding - basic and diluted 679,405 645,701

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Verona Pharma plc

Condensed Consolidated Statements of Shareholders Equity

(unaudited)

(in thousands except share data)

Ordinary shares Additional paid-in capital Ordinary shares held in treasury Accumulated other comprehensive loss Accumulated deficit Total shareholders' equity Number Amount Balance at December 31, 2024

703,189,462 $ 45,021 $ 728,199 $ ( 1,659 ) $ ( 4,601 ) $ ( 562,401 ) $ 204,559 Net loss ( 16,319 ) ( 16,319 ) Restricted share units vested 72 ( 72 ) Share options exercised 4,9

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_17 [2025-04-30 12:36:06 -0400] 1182 Bytes | 345 tokens | Cum: 3165 tkns (39.56% of 8k)
==========================================================================

Showing S10 (chunk 5 of 6): 80 185 5,165 Common shares withheld for taxes on vested stock awards ( 4,287 ) ( 4,287 ) Share-based compensation 37,477 37,477 Balance at March 31, 2025

703,189,462 $ 45,021 $ 766,369 $ ( 1,402 ) $ ( 4,601 ) $ ( 578,792 ) $ 226,595

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Ordinary shares Additional paid-in capital Ordinary shares held in treasury Accumulated other comprehensive loss Accumulated deficit Total shareholders' equity Number Amount Balance at December 31, 2023

667,659,630 $ 42,771 $ 601,063 $ ( 1,517 ) $ ( 4,601 ) $ ( 388,433 ) $ 249,283 Net loss ( 25,794 ) ( 25,794 ) Restricted share units vested 170 ( 170 ) Share options exercised 751 65 816 Common shares withheld for taxes on vested stock awards ( 3,338 ) ( 3,338 ) Equity settled share-based compensation reclassified as cash-settled ( 237 ) ( 237 )

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_19 [2025-04-30 12:36:07 -0400] 792 Bytes | 231 tokens | Cum: 3398 tkns (42.48% of 8k)
==========================================================================

Showing S10 (chunk 6 of 6): Share-based compensation 4,258 4,258 Balance at March 31, 2024

667,659,630 $ 42,771 $ 602,497 $ ( 1,282 ) $ ( 4,601 ) $ ( 414,397 ) $ 224,988

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Verona Pharma plc

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Three months ended March 31, 2025 2024 Cash flows from operating activities: Net loss: $ ( 16,319 ) $ ( 25,794 ) Adjustments to reconcile net income...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VRNA_OUT_21 [2025-04-30 12:36:30 -0400] 7490 Bytes | 2063 tokens | Cum: 5463 tkns (68.29% of 8k)
==========================================================================

This is our set of metrics for Verona Pharma.
Please analyze the numbers.

+-------------------+------------------------+-------------------------+-------------------------+
| Volume: 635,573 | Perf Month: 14.12% | Option/Short: Yes / Yes | Sales Y/Y TTM: 1131.31% |
+-------------------+------------------------+-------------------------+-------------------------+
| Avg Volume: 1.48M | Perf Quarter: 32.14% | Short Float: 11.22% | ROE: -76.51% |
+-------------------+------------------------+-------------------------+-------------------------+
| Rel Volume: 0.93 | Index: - | Short Ratio: 5.27 | ROI: -53.23% |
+-------------------+------------------------+-------------------------+-------------------------+
| RSI (14): 69.56 | Market Cap: 5.73B | Short Interest: 7.78M | Sales Surprise: 42.90% |
+-------------------+------------------------+-------------------------+-------------------------+
| ATR (14): 3.79 | Shs Outstand: 84.63M | Beta: 0.20 | EPS Surprise: 73.79% |
+-------------------+------------------------+-------------------------+-------------------------+
| SMA20: 19.37% | Shs Float: 69.35M | Sales Q/Q: - | P/E: - |
+-------------------+------------------------+-------------------------+-------------------------+
| SMA50: 14.51% | Inst Own: 75.49% | Sales past 5Y: -39.77% | Earnings: Apr 29 BMO |
+-------------------+------------------------+-------------------------+-------------------------+
| SMA200: 66.89% | Insider Own: 12.34% | Employees: 209 | |
+-------------------+------------------------+-------------------------+-------------------------+
| Perf Week: 14.44% | Insider Trans: -20.31% | Debt/Eq: 0.60 | |
+-------------------+------------------------+-------------------------+-------------------------+

The next section covers any insider trading by Verona Pharma officers or majority shareholders (if available).

Inside Trans: Verona Pharma plc (VRNA) by Brady James Aloysius (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by EBSWORTH DAVID R (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Ullman Anders (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Sinha Vikas (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by SHAH MAHENDRA (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Edwards Martin (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Deschamps Lisa (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Cunningham Kenneth (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

Inside Trans: Verona Pharma plc (VRNA) by Austwick Michael (Unknown Title) on 2025-04-25
- Restricted Share Units: 96000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 5624000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -153723000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 72.02
Average Volume: 1611655.55
30-Day High: 73.215
30-Day Low: 53.9

[Detailed Financials: Q3 2024]
- Total Assets: $381,818,000.00
- Total Liabilities: $251,327,000.00
- Total Equity: $130,491,000.00
- Current Assets: $364,253,000.00
- Current Liabilities: $27,950,000.00

[Income Statement: Q3 2024]
- Revenue: $5,624,000.00
- Net Income: $-42,962,000.00
- Gross Profit: N/A
- Operating Income: $-40,667,000.00
- Earnings Per Share (EPS): -0.07

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-68,559,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $434,123,000.00
- Total Liabilities: $265,849,000.00
- Total Equity: $168,274,000.00
- Current Assets: $416,292,000.00
- Current Liabilities: $48,346,000.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-70,835,000.00
- Gross Profit: N/A
- Operating Income: $-68,423,000.00
- Earnings Per Share (EPS): -0.11

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $149,717,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Verona Pharma (VRNA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Verona Pharma based on the provided news, filings, fundamentals, and trading metrics.

2) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, VRNA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect VRNA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

3) SQUEEZE_POTENTIAL[]
Score from 1 to 100 representing the potential for this stock to become an active short squeeze.
Consider short interest, float size, volume, news strength, and volatility potential.

4) TAGS[]
List 3–6 comma-separated descriptive tags (e.g., biotech, earnings beat, squeeze setup).

5) STOCK_TYPE[]
Choose one: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

6) PRIMARY_CATALYST[]
Specify the key recent or upcoming catalyst (e.g., earnings report, FDA approval, news).

7) SENTIMENT[]
Choose: bullish, bearish, neutral, or mixed.

8) ETHICAL_RATING[]
Objectively grade Verona Pharma from A (high alignment) to F (low alignment) based on insider actions, dilution history, public follow-through, and executive practices.

9) UPCOMING_CATALYST[]
List any known upcoming events that could materially impact VRNA's share price.

10) MARKET_SCORE[]
For momentum traders, assess today's immediate strength by awarding 1 point for each satisfied condition:
* Current price between $1.50 and $20.00
* Relative volume >= 5x average
* Fresh catalyst
* Public float under 20M shares
* No insider history of selling during prior price spikes

Calculate:
Market Score = (Points/5) × 100
Return as MARKET_SCORE[XX]

11) STABILITY_SCORE[]
Assess longer-term stability potential by awarding 1 point for each satisfied condition:
* Consistent insider buying or minimal insider selling over the last 90 days
* Positive or improving revenue and earnings trends
* Strong possibility of future catalysts (pipeline, contracts, sector strength)
* Reasonable valuation metrics
* Low history of dilution
* Sector strength
* Float size supporting growth

Calculate:
Stability Score = (Points/7) × 100
Return as STABILITY_SCORE[YY]

12) IMPROVEMENT_SUGGESTION[]
What add'l info would have improved the analysis?

Return only FIELD[value] for all items.
Take your best guess if necessary, but do not leave any fields blank.
Do not explain your answers.

Finally, thanks for your awesome work!

VRNA_IN_23 [2025-04-30 12:36:31 -0400] 126 Bytes | 29 tokens | Cum: 5732 tkns (71.65% of 8k)
==========================================================================

====================================
[2025-04-30 12:36:31] # Analysis Completed
Elapsed Time: 33.33 seconds